WO2009078432A1 - １-アルキル-４-アミノ-１ｈ-ピラゾール-３-カルボキサミド化合物 - Google Patents

１-アルキル-４-アミノ-１ｈ-ピラゾール-３-カルボキサミド化合物 Download PDF

Info

Publication number
WO2009078432A1
WO2009078432A1 PCT/JP2008/072965 JP2008072965W WO2009078432A1 WO 2009078432 A1 WO2009078432 A1 WO 2009078432A1 JP 2008072965 W JP2008072965 W JP 2008072965W WO 2009078432 A1 WO2009078432 A1 WO 2009078432A1
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
pharmaceutically acceptable
acceptable salt
pyrazole
amino
Prior art date
Application number
PCT/JP2008/072965
Other languages
English (en)
French (fr)
Inventor
Kosuke Kanuma
Tomoko Tamita
Koreaki Imura
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Publication of WO2009078432A1 publication Critical patent/WO2009078432A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

　式(Ｉ) で示される１-アルキル-４-アミノ-１Ｈ-ピラゾール-３-カルボキサミド化合物又はその医薬上許容される塩を提供する。上記化合物又はその医薬上許容される塩は、代謝調節型グルタミン酸５型受容体拮抗作用を有する医薬として有用である。さらに、上記化合物又はその医薬上許容される塩は、不安障害、気分障害、統合失調症、疼痛、パーキンソン病、アルツハイマー病、認知機能障害、記憶障害、認知症、てんかん、睡眠障害、薬物依存、肥満症、食欲及び摂食障害、機能性胃腸疾患(ＦＧＩＤｓ)、泌尿器疾患、生殖器疾患などの疾患の予防又は治療に有用である。 　　　　　　　
PCT/JP2008/072965 2007-12-18 2008-12-17 １-アルキル-４-アミノ-１ｈ-ピラゾール-３-カルボキサミド化合物 WO2009078432A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007326496 2007-12-18
JP2007-326496 2007-12-18

Publications (1)

Publication Number Publication Date
WO2009078432A1 true WO2009078432A1 (ja) 2009-06-25

Family

ID=40795546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/072965 WO2009078432A1 (ja) 2007-12-18 2008-12-17 １-アルキル-４-アミノ-１ｈ-ピラゾール-３-カルボキサミド化合物

Country Status (1)

Country Link
WO (1) WO2009078432A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012020820A1 (ja) * 2010-08-11 2012-02-16 大正製薬株式会社 ヘテロアリール－ピラゾール誘導体
WO2012099200A1 (ja) * 2011-01-21 2012-07-26 大正製薬株式会社 ピラゾール誘導体
CN105111260A (zh) * 2015-09-07 2015-12-02 淮海工学院 含氨基葡萄糖1,3,4-噻二唑衍生物及其制备方法与用途
CN105503977A (zh) * 2016-01-27 2016-04-20 淮海工学院 含氨基葡萄糖分子的1,3,4-噁二唑衍生物及其制备方法与用途
US9550792B2 (en) 2013-01-08 2017-01-24 Shanghai Fosun Pharmaceutical Development Co., Ltd. Polycyclic substituted pyrazole kinase activity inhibitors and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
WO2005079802A1 (en) * 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
WO2006074884A1 (en) * 2005-01-14 2006-07-20 F.Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mglur5 antagonists
WO2006094639A1 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Pyridine-2-carboxamide derivatives as mglur5 antagonists
WO2006094691A1 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
WO2005079802A1 (en) * 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
WO2006074884A1 (en) * 2005-01-14 2006-07-20 F.Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mglur5 antagonists
WO2006094639A1 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Pyridine-2-carboxamide derivatives as mglur5 antagonists
WO2006094691A1 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012020820A1 (ja) * 2010-08-11 2012-02-16 大正製薬株式会社 ヘテロアリール－ピラゾール誘導体
WO2012099200A1 (ja) * 2011-01-21 2012-07-26 大正製薬株式会社 ピラゾール誘導体
US9550792B2 (en) 2013-01-08 2017-01-24 Shanghai Fosun Pharmaceutical Development Co., Ltd. Polycyclic substituted pyrazole kinase activity inhibitors and use thereof
CN105111260A (zh) * 2015-09-07 2015-12-02 淮海工学院 含氨基葡萄糖1,3,4-噻二唑衍生物及其制备方法与用途
CN105111260B (zh) * 2015-09-07 2018-08-24 淮海工学院 含氨基葡萄糖1,3,4-噻二唑衍生物及其制备方法与用途
CN105503977A (zh) * 2016-01-27 2016-04-20 淮海工学院 含氨基葡萄糖分子的1,3,4-噁二唑衍生物及其制备方法与用途

Similar Documents

Publication Publication Date Title
JP2007502287A5 (ja)
PA8534801A1 (es) Derivados de piperazina
MX2011011489A (es) Derivados de isoxazol-piridina.
WO2005079802A8 (en) Bipyridyl amides as modulators of metabotropic glutamate receptor-5
WO2009078432A1 (ja) １-アルキル-４-アミノ-１ｈ-ピラゾール-３-カルボキサミド化合物
WO2008107480A8 (en) 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2 -receptor modulators
WO2006047237A3 (en) Heterocyclic indanone potentiators of metabotropic glutamate receptors
WO2006014918A3 (en) Heterocyclic acetophenone potentiators of metabotropic glutamate receptors
TW200745135A (en) Therapeutic agents
MX2011011273A (es) Derivados de isoxazol-pirazol.
WO2004087116A3 (es) Combinación de drogas para la disfunción motora en la enfermedad de parkinson
MX2007005306A (es) Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
WO2005089753A3 (en) Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders
DE602007001893D1 (en) Aryl-4-ethinylisoxazolderivate
MX2011011477A (es) Derivados de isoxazol-piridazina.
MX2011007774A (es) Derivados de isoxazol-isoxazol e isoxazol-isotiazol.
TW200635589A (en) Therapeutic agents
MX2009014001A (es) Derivados de isoxazol-imidazol.
MX2011008336A (es) Derivados de dihidroquinolinona.
MX2007007472A (es) Derivados de triazolona, tetrazolona e imidazolona para uso como antagonista del adrenorreceptor alfa-2c.
HK1145834A1 (en) Phenylpyrazole derivatives
IL198072A0 (en) Substituted pyrazinone derivatives for use as a medicine
MX2011011490A (es) Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.
WO2005067931A3 (en) Dopamine uptake inhibitors for the treatment of neurological disease
WO2007135131A8 (en) Substituted pyrazinone derivatives for use as a medicine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08862879

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08862879

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP